Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)
NCT04988555 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- February 28, 2022
- Completion date
- December 31, 2027
- Enrollment
- 606 (estimated)
- Sites
- 104
Conditions
As the registry lists them; a condition with its own page is linked.
leukemia, lymphocytic, acute, leukemia, myeloid, acute, multiple myeloma, myelodysplastic syndromes